![]() |
市場調查報告書
商品編碼
1395011
人工胰臟設備系統 (APDS) 市場 - 按設備類型(閾值暫停設備系統、控制範圍 (CTR) 系統、控制目標 (CTT) 系統)、按最終用途(醫院和診所、家庭護理) - 全球預測,2023- 2032Artificial Pancreas Device Systems (APDS) Market - By Device Type (Threshold Suspend Device Systems, Control-to-range (CTR) Systems, Control-to-target (CTT) Systems), By End-use (Hospitals and Clinics, Homecare) - Global Forecast, 2023-2032 |
在廣泛的研究和開發工作取得可喜成果的推動下,全球人工胰臟設備系統 (APDS) 市場 2023 年至 2032 年間的CAGR將達到 8.8%。突破性成果展示了這些系統在管理糖尿病方面的功效,為加強病患照護帶來了希望。
例如,2023 年3 月,兒科人工胰臟(PEDAP) 試驗是一項在美國三個兒科糖尿病中心進行的為期13 週的隨機對照研究,結果顯示,透過人工胰臟可以增強2 至5 歲患有1 型糖尿病的幼兒的血糖控制。胰臟技術。在美國國立衛生研究院下屬的國家糖尿病、消化和腎臟疾病研究所 (NIDDK) 的資助下,研究結果發表在《新英格蘭醫學雜誌》。該技術也稱為閉迴路控制,可作為整合式糖尿病管理系統,利用連續血糖監測 (CGM) 來追蹤血糖水平,並根據需要透過胰島素幫浦自動管理胰島素。
隨著臨床試驗顯示出正面的結果,對 APDS 的需求不斷成長。該技術在自動化胰島素輸送和維持血糖水平方面的潛力引起了人們的關注,將 APDS 定位為糖尿病管理創新的燈塔。這種樂觀情緒推動了人工胰臟裝置系統 (APDS) 市場的擴張,因為它正朝著改變全球糖尿病照護的方向發展。
整個人工胰臟設備系統(APDS)市場根據設備類型、最終用途和區域進行分類。
從 2023 年到 2032 年,控制範圍 (CTR) 設備細分市場將呈現顯著成長。這些創新系統可在目標範圍內提供精確的血糖管理,重新定義糖尿病護理。 CTR 技術可確保最佳血糖水平,降低低血糖和高血糖風險。 CTR 設備能夠根據連續血糖監測儀 (CGM) 的即時資料微調胰島素輸送,徹底改變了糖尿病管理。社交胰臟設備系統市場收入的成長得益於改善糖尿病患者健康結果和提高生活品質的承諾,從而增強了這些先進系統的吸引力。
家庭護理領域從 2023 年到 2032 年將實現顯著的CAGR。APDS 提供了變革性的轉變,使個人能夠在家中方便地管理自己的狀況。借助利用連續血糖監測儀和自動胰島素輸送的整合系統,APDS 使患者無需住院即可維持最佳血糖水平。這一趨勢反映了向個人化、便利照護的根本轉變,隨著居家照護成為現代糖尿病管理策略的基石,推動了人工胰臟設備系統市場的發展。
歐洲人工胰臟裝置系統 (APDS) 市場從 2023 年到 2032 年將呈現出值得稱讚的CAGR。該地區採用 APDS 技術,尋求高效、自動化的血糖控制解決方案。 APDS 專注於提高患者治療效果和生活品質,整合了連續血糖監測和胰島素輸送,因其便利性和有效性而受到關注。歐洲市場的成長反映了對創新、以患者為中心的糖尿病護理的漸進方法,促進了整個非洲大陸對 APDS 解決方案不斷成長的需求。例如,2023 年 11 月,英格蘭和威爾斯的 NHS 計劃為超過 150,000 名 1 型糖尿病患者(包括成人和兒童)提供人工胰腺,專家稱讚此舉是革命性的,可以挽救生命。
Global Artificial Pancreas Device Systems (APDS) Market will witness 8.8% CAGR between 2023 and 2032, propelled by promising outcomes from extensive research and development efforts. Breakthroughs showcase the efficacy of these systems in managing diabetes, offering hope for enhanced patient care.
For instance, in March 2023, The Pediatric Artificial Pancreas (PEDAP) Trial, a 13-week randomized controlled study across three pediatric diabetes centers in the United States, revealed enhanced blood glucose control in toddlers aged 2 to 5 with type 1 diabetes through Artificial Pancreas Technology. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, findings were published in the New England Journal of Medicine. This technology, also termed closed-loop control, acts as an integrated diabetes management system, utilizing continuous glucose monitoring (CGM) to track glucose levels and automatically administering insulin as necessary via an insulin pump.
As clinical trials demonstrate positive results, the demand for APDS grows. The technology's potential to automate insulin delivery and maintain glucose levels garners attention, positioning APDS as a beacon of innovation in diabetes management. This optimism fuels the artificial pancreas device systems (APDS) market expansion as it moves towards transforming diabetes care globally.
The overall Artificial Pancreas Device Systems (APDS) Market is classified based on device type, end-use, and region.
Control-to-range (CTR) devices segment will exhibit significant growth from 2023 to 2032. Offering precise glucose management within target ranges, these innovative systems redefine diabetes care. CTR technology ensures optimal blood glucose levels, mitigating both hypoglycemia and hyperglycemia risks. With their ability to fine-tune insulin delivery based on real-time data from continuous glucose monitors (CGM), CTR devices revolutionize diabetes management. The art of social pancreas device systems market revenue is propelled by the promise of improved health outcomes and enhanced quality of life for individuals navigating diabetes, amplifying the appeal of these advanced systems.
Homecare segment will register a noteworthy CAGR from 2023 to 2032. APDS offers a transformative shift, allowing individuals to manage their condition conveniently at home. With integrated systems utilizing continuous glucose monitors and automated insulin delivery, APDS empowers patients to maintain optimal blood glucose levels without hospital visits. This trend reflects a fundamental shift towards personalized, accessible care, driving the artificial pancreas device system market as home care becomes a cornerstone in modern diabetes management strategies.
Europe artificial pancreas device systems (APDS) market will showcase a commendable CAGR from 2023 to 2032. The region embraces APDS technology, seeking efficient, automated solutions for glucose control. With a focus on enhancing patient outcomes and quality of life, APDS integrates continuous glucose monitoring and insulin delivery, gaining traction for its convenience and efficacy. The market's growth in Europe reflects a progressive approach towards innovative, patient-centric diabetes care, fostering a rising demand for APDS solutions across the continent. For instance, in November 2023, The NHS in England and Wales planned to provide over 150,000 individuals, both adults and children with type 1 diabetes, with an artificial pancreas-a move praised by experts as revolutionary and life-saving.